BMO Capital analyst John McNulty raised the firm’s price target on Ashland to $105 from $97 and keeps a Market Perform rating on the shares after its Q2 earnings beat. Following significant destocking in FY23, Ashland executed on its efforts to reduce production to better match the demand of its customers and as such has seen its profitability improve, the analyst tells investors in a research note. BMO adds that it continues to look for a normalization of Ashland profits in the next few quarters to get greater comfort on the company’s new base line.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASH:
- Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners
- Ashland Investor Update Scheduled for April 30, 2024
- Ashland narrows FY24 revenue view to $2.15B-$2.23B from $2.15B-$2.25B
- Ashland reports financial results1 for second quarter fiscal 2024; issues outlook for third quarter and full-year fiscal 2024
- Ashland sees Q3 revenue $560M-$580M, consensus $583.89M